Trial Profile
Evaluation of the immunogenicity and safety of a booster dose of Pfizer's 13-valent pneumococcal conjugate vaccine (PCV) in children primed with 2 doses of either GSK's 10-valent PCV or Pfizer's 13-valent PCV in the Slovak Republic.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PCV-MIXED-SCHEDULE
- 27 Feb 2013 New trial record